Literature DB >> 22870431

Understanding Personalized Medicine in Rheumatoid Arthritis: A Clinician's Guide to the Future.

Paula I Burgos1, Maria I Danila, James M Kelley, Laura B Hughes, S Louis Bridges.   

Abstract

Personalized medicine refers to the utilization of technologies at the molecular level to understand disease processes and improve health outcomes. In rheumatoid arthritis (RA) some factors associated with disease outcome have been identified. These factors have not yet been integrated into a clinically useful tool to predict disease outcome in individual patients. Developments in pharmacogenomics are moving the field forward quite rapidly. Genetic variants, which may have a role in drug metabolism mediating either drug response or toxicity, have been identified for both traditional disease modifying antirheumatic drugs and biologic agents. Choosing a medication based on a patient's characteristics (sociodemographic, clinical, genetic) will result in better utilization of resources and better clinical outcomes. The ethical, political, and legal implications of personalized medicine need to be considered as well.

Entities:  

Keywords:  biomarkers; disease-modifying antirheumatic drugs (DMARDs); personalized medicine; pharmacogenetics; pharmacogenomics

Year:  2009        PMID: 22870431      PMCID: PMC3383485          DOI: 10.1177/1759720X09351778

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN: 1759-720X            Impact factor:   5.346


  66 in total

Review 1.  Remission and radiographic progression in rheumatoid arthritis.

Authors:  A E Voskuyl; B A C Dijkmans
Journal:  Clin Exp Rheumatol       Date:  2006 Nov-Dec       Impact factor: 4.473

2.  Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.

Authors:  Alf Kastbom; Johan Bratt; Sofia Ernestam; Jon Lampa; Leonid Padyukov; Peter Söderkvist; Thomas Skogh
Journal:  Arthritis Rheum       Date:  2007-02

3.  Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.

Authors:  Thierry Dervieux; Neal Greenstein; Joel Kremer
Journal:  Arthritis Rheum       Date:  2006-10

Review 4.  Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis.

Authors:  P Emery; I B McInnes; R van Vollenhoven; M C Kraan
Journal:  Rheumatology (Oxford)       Date:  2007-12-18       Impact factor: 7.580

5.  Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis.

Authors:  Chunyu Liu; Franak Batliwalla; Wentian Li; Annette Lee; Ronenn Roubenoff; Evan Beckman; Houman Khalili; Aarti Damle; Marlena Kern; Richard Furie; Josée Dupuis; Robert M Plenge; Marieke J H Coenen; Timothy W Behrens; John P Carulli; Peter K Gregersen
Journal:  Mol Med       Date:  2008 Sep-Oct       Impact factor: 6.354

6.  The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.

Authors:  Andrzej Pawlik; Magdalena Herczynska; Mateusz Kurzawski; Krzysztof Safranow; Violetta Dziedziejko; Marek Drozdzik
Journal:  Pharmacogenomics       Date:  2009-02       Impact factor: 2.533

7.  Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.

Authors:  A Kavanaugh; S Rosengren; S J Lee; D Hammaker; G S Firestein; K Kalunian; N Wei; D L Boyle
Journal:  Ann Rheum Dis       Date:  2007-07-20       Impact factor: 19.103

8.  Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis.

Authors:  Marieke J H Coenen; Erik J M Toonen; Hans Scheffer; Timothy R D J Radstake; Pilar Barrera; Barbara Franke
Journal:  Pharmacogenomics       Date:  2007-07       Impact factor: 2.533

9.  Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis.

Authors:  Shouvik Dass; Andy C Rawstron; Edward M Vital; Karen Henshaw; Dennis McGonagle; Paul Emery
Journal:  Arthritis Rheum       Date:  2008-10

10.  Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study.

Authors:  M H Buch; D L Boyle; S Rosengren; B Saleem; R J Reece; L A Rhodes; A Radjenovic; A English; H Tang; G Vratsanos; P O'Connor; G S Firestein; P Emery
Journal:  Ann Rheum Dis       Date:  2008-09-04       Impact factor: 19.103

View more
  3 in total

1.  Nonassociation of homocysteine gene polymorphisms with treatment outcome in South Indian Tamil Rheumatoid Arthritis patients.

Authors:  Niveditha Muralidharan; Reena Gulati; Durga Prasanna Misra; Vir S Negi
Journal:  Clin Exp Med       Date:  2017-08-18       Impact factor: 3.984

2.  Reduced folate carrier-1 80G > A gene polymorphism is not associated with methotrexate treatment response in South Indian Tamils with rheumatoid arthritis.

Authors:  Niveditha Muralidharan; Christina Mary Mariaselvam; C B Mithun; Vir Singh Negi
Journal:  Clin Rheumatol       Date:  2015-03-15       Impact factor: 2.980

3.  Factors associated with drug survival on first biologic therapy in patients with rheumatoid arthritis: a population-based cohort study.

Authors:  Mohammad E Naffaa; Fadi Hassan; Avivit Golan-Cohen; Eugene Merzon; Ilan Green; Amir Saab; Ziv Paz
Journal:  Rheumatol Int       Date:  2021-09-16       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.